Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Proteomics. 2010 Sep 10;73(10):1851-63. doi: 10.1016/j.jprot.2010.05.015. Epub 2010 Jun 1.

Lung cancer proteomics, clinical and technological considerations.

Author information

  • 1Karolinska Biomics Center, Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. janne.lehtio@ki.se

Abstract

The overall survival of lung cancer patients is disappointingly low. This is due to several factors, including the lack of an effective screening strategy to detect tumors at a potentially curable early stage, a marked resistance of lung cancer cells to drug treatment and a still superficial knowledge about the multifactorial cellular networks that are activated or suppressed during cancer progression. Furthermore, the armamentarium of clinicians and researchers in the field does not yet include reliable biomarkers to predict tumor response to treatment and foresee the natural history of the disease. In the present situation, a potential breakthrough is presented by proteomics technologies with the potential to discover relevant biomarkers which can be accurately quantified in multiplexed assays. Proteomics field can also contribute greatly in the understanding of mechanisms in tumor progression and treatment response. In this review we will describe the work that is being done in the field of lung cancer proteomics, focusing on clinically relevant questions that need to be addressed and on the possible applications of novel technologies.

Copyright © 2010 Elsevier B.V. All rights reserved.

PMID:
20685322
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk